Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

497 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Heterogeneity of aerobic fitness changes with exercise training in progressive multiple sclerosis: Secondary, exploratory analysis of data from the CogEx trial.
Motl RW, Sandroff BM, Hernandez RS, Amato MP, Brichetto G, Chataway J, Chiaravalloti ND, Cutter G, Dalgas U, DeLuca J, Farrell R, Feys P, Filippi M, Freeman J, Inglese M, Meza C, Rocca MA, Salter A, Feinstein A; CogEx Research Team. Motl RW, et al. Among authors: salter a. Mult Scler J Exp Transl Clin. 2024 Dec 5;10(4):20552173241301030. doi: 10.1177/20552173241301030. eCollection 2024 Oct-Dec. Mult Scler J Exp Transl Clin. 2024. PMID: 39651332 Free PMC article.
Retinal architecture predicts pupillary reflex metrics in MS.
Salter AR, Conger A, Frohman TC, Zivadinov R, Eggenberger E, Calabresi P, Cutter G, Balcer L, Frohman EM. Salter AR, et al. Mult Scler. 2009 Apr;15(4):479-86. doi: 10.1177/1352458508100503. Epub 2008 Dec 17. Mult Scler. 2009. PMID: 19091882
A one-year prospective, randomized, placebo-controlled, quadruple-blinded, phase II safety pilot trial of combination therapy with interferon beta-1a and mycophenolate mofetil in early relapsing-remitting multiple sclerosis (TIME MS).
Remington GM, Treadaway K, Frohman T, Salter A, Stüve O, Racke MK, Hawker K, Agosta F, Sormani MP, Filippi M, Frohman EM. Remington GM, et al. Among authors: salter a. Ther Adv Neurol Disord. 2010 Jan;3(1):3-13. doi: 10.1177/1756285609355851. Ther Adv Neurol Disord. 2010. PMID: 21180632 Free PMC article.
A randomized, blinded, parallel-group, pilot trial of mycophenolate mofetil (CellCept) compared with interferon beta-1a (Avonex) in patients with relapsing-remitting multiple sclerosis.
Frohman EM, Cutter G, Remington G, Gao H, Rossman H, Weinstock-Guttman B, Durfee JE, Conger A, Carl E, Treadaway K, Lindzen E, Salter A, Frohman TC, Shah A, Bates A, Cox JL, Dwyer MG, Stüve O, Greenberg BM, Racke MK, Zivadinov R. Frohman EM, et al. Among authors: salter a. Ther Adv Neurol Disord. 2010 Jan;3(1):15-28. doi: 10.1177/1756285609353354. Ther Adv Neurol Disord. 2010. PMID: 21180633 Free PMC article.
Got milk?
Cutter G, Salter A. Cutter G, et al. Among authors: salter a. Ann Neurol. 2011 Jul;70(1):3-4. doi: 10.1002/ana.22507. Ann Neurol. 2011. PMID: 21786294 No abstract available.
Natural history of multiple sclerosis symptoms.
Kister I, Bacon TE, Chamot E, Salter AR, Cutter GR, Kalina JT, Herbert J. Kister I, et al. Int J MS Care. 2013 Fall;15(3):146-58. doi: 10.7224/1537-2073.2012-053. Int J MS Care. 2013. PMID: 24453777 Free PMC article.
497 results